Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
NDC API
0
VMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 591.5 g/mol |
---|---|
Molecular Formula | C12H17NO20S3-4 |
XLogP3 | -5.6 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 21 |
Rotatable Bond Count | 6 |
Exact Mass | 590.95060545 g/mol |
Monoisotopic Mass | 590.95060545 g/mol |
Topological Polar Surface Area | 376 Ų |
Heavy Atom Count | 36 |
Formal Charge | -4 |
Complexity | 1040 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 6 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Heparin sodium in plastic container |
Active Ingredient | Heparin sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | 10,000 units/ml; 5,000 units/ml; 20,000 units/ml; 1,000 units/ml |
Market Status | Prescription |
Company | Fresenius Kabi Usa |
2 of 4 | |
---|---|
Drug Name | Heparin sodium preservative free |
Active Ingredient | Heparin sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | 10,000 units/ml; 1,000 units/ml |
Market Status | Prescription |
Company | Hospira; Shenzhen Techdow; Pfizer; Fresenius Kabi Usa; Sagent Pharms |
3 of 4 | |
---|---|
Drug Name | Heparin sodium in plastic container |
Active Ingredient | Heparin sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | 10,000 units/ml; 5,000 units/ml; 20,000 units/ml; 1,000 units/ml |
Market Status | Prescription |
Company | Fresenius Kabi Usa |
4 of 4 | |
---|---|
Drug Name | Heparin sodium preservative free |
Active Ingredient | Heparin sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | 10,000 units/ml; 1,000 units/ml |
Market Status | Prescription |
Company | Hospira; Shenzhen Techdow; Pfizer; Fresenius Kabi Usa; Sagent Pharms |
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9939
Submission : 1992-11-02
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31703
Submission : 2017-04-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25556
Submission : 2011-12-20
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-02-22
Pay. Date : 2014-07-25
DMF Number : 20541
Submission : 2007-03-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29154
Submission : 2015-03-06
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19658
Submission : 2006-08-04
Status : Inactive
Type : II
Registration Number : 227MF10152
Registrant's Address : Via Pacinotti, 3 41043 Corlo di Formigine (Modena) Italy
Initial Date of Registration : 2015-06-01
Latest Date of Registration :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10596
Submission : 1993-12-07
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20905
Submission : 2007-09-25
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19038
Submission : 2005-12-15
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21950
Submission : 2008-09-01
Status : Inactive
Type : II
RLD : No
TE Code :
Brand Name : INNOHEP
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 20,000 IU/ML
Approval Date : 2000-07-14
Application Number : 20484
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code :
Brand Name : NORMIFLO
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10,000 UNITS/0.5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 1997-05-23
Application Number : 20227
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : NORMIFLO
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 5,000 UNITS/0.5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 1997-05-23
Application Number : 20227
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : FRAGMIN
Dosage Form : INJECTABLE;SUBCUTANEOUS
Dosage Strength : 2,500IU/0.2ML (12,500IU/ML)
Approval Date : 1994-12-22
Application Number : 20287
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : FRAGMIN
Dosage Form : INJECTABLE;SUBCUTANEOUS
Dosage Strength : 10,000IU/ML (10,000IU/ML)
Approval Date : 1998-01-30
Application Number : 20287
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : FRAGMIN
Dosage Form : INJECTABLE;SUBCUTANEOUS
Dosage Strength : 7,500IU/0.3ML (25,000IU/ML)
Approval Date : 2002-04-04
Application Number : 20287
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : FRAGMIN
Dosage Form : INJECTABLE;SUBCUTANEOUS
Dosage Strength : 95,000IU/3.8ML (25,000IU/ML)
Approval Date : 2002-04-04
Application Number : 20287
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : No
TE Code :
Brand Name : FRAGMIN
Dosage Form : INJECTABLE;SUBCUTANEOUS
Dosage Strength : 95,000IU/9.5ML (10,000IU/ML)
Approval Date : 2002-04-04
Application Number : 20287
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : FRAGMIN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 7,500 IU/0.75ML
Approval Date : 2002-04-04
Application Number : 20287
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code :
Brand Name : FRAGMIN
Dosage Form : INJECTABLE;SUBCUTANEOUS
Dosage Strength : 12,500IU/0.5ML (25,000IU/ML)
Approval Date : 2007-05-01
Application Number : 20287
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Regulatory Info :
Registration Country : Italy
Brand Name : Fluxum
Dosage Form : 4.250Parnaparin Iu Axa 0.4 Ml 6 Units Parenteral Use
Dosage Strength : 6 Syringes SC 4,250 IU aXa 0.4 ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Fluxum
Dosage Form : 8.500Parnaparin Iu Axa 0,8Ml 6 Units Parenteral Use
Dosage Strength : 6 Syringes SC 8,500 IU aXa 0.8 ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Brand Name : Lyman 40000 Mono Spray
Dosage Form : L?s
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : Innohep
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 10,000 ANTI XA
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Innohep
Dosage Form : SOLUTION FOR INJECTION, PRE-FILLED SYRINGE
Dosage Strength : 10,000 ANTI XA IU
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Fragmin
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 2500 IU / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Fragmin
Dosage Form : SOLUTION FOR INJECTION, PRE-FILLED SYRINGE
Dosage Strength : 10000 IU
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Switzerland
Brand Name : Fragmin
Dosage Form : Inj Solution
Dosage Strength : 5000iu/0.2ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Fragmin
Dosage Form : Inj Loose
Dosage Strength : 18000iu/0.72ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Fraxiforte 0.8 ml
Dosage Form : Inj Loose
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
20
PharmaCompass offers a list of Dalteparin sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dalteparin sodium manufacturer or Dalteparin sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dalteparin sodium manufacturer or Dalteparin sodium supplier.
PharmaCompass also assists you with knowing the Dalteparin sodium API Price utilized in the formulation of products. Dalteparin sodium API Price is not always fixed or binding as the Dalteparin sodium Price is obtained through a variety of data sources. The Dalteparin sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nadroparin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nadroparin, including repackagers and relabelers. The FDA regulates Nadroparin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nadroparin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nadroparin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nadroparin supplier is an individual or a company that provides Nadroparin active pharmaceutical ingredient (API) or Nadroparin finished formulations upon request. The Nadroparin suppliers may include Nadroparin API manufacturers, exporters, distributors and traders.
click here to find a list of Nadroparin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nadroparin DMF (Drug Master File) is a document detailing the whole manufacturing process of Nadroparin active pharmaceutical ingredient (API) in detail. Different forms of Nadroparin DMFs exist exist since differing nations have different regulations, such as Nadroparin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nadroparin DMF submitted to regulatory agencies in the US is known as a USDMF. Nadroparin USDMF includes data on Nadroparin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nadroparin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nadroparin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Nadroparin Drug Master File in Japan (Nadroparin JDMF) empowers Nadroparin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Nadroparin JDMF during the approval evaluation for pharmaceutical products. At the time of Nadroparin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Nadroparin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Nadroparin Drug Master File in Korea (Nadroparin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Nadroparin. The MFDS reviews the Nadroparin KDMF as part of the drug registration process and uses the information provided in the Nadroparin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Nadroparin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Nadroparin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Nadroparin suppliers with KDMF on PharmaCompass.
Nadroparin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nadroparin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nadroparin GMP manufacturer or Nadroparin GMP API supplier for your needs.
A Nadroparin CoA (Certificate of Analysis) is a formal document that attests to Nadroparin's compliance with Nadroparin specifications and serves as a tool for batch-level quality control.
Nadroparin CoA mostly includes findings from lab analyses of a specific batch. For each Nadroparin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nadroparin may be tested according to a variety of international standards, such as European Pharmacopoeia (Nadroparin EP), Nadroparin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nadroparin USP).